Jia Li
Jia Li has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina Chirikova
University of California 10 Department of Epidemiology and Biostatistics San Francisco, California
8 shared publications - Elisa V. Bandera
Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute , New Brunswick, NJ
8 shared publications - Farzin Khosrow-Khavar
Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
8 shared publications - Jennifer Anne Doherty
Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
8 shared publications - Juraj Kavecansky
Division of Research, Kaiser Permanente Northern California, Pleasanton, California
8 shared publications - Laurie Grieshober
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
8 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Data from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Background:Compared with non-Hispanic White (NHW) women, Black women with epithelial ovarian cancer (EOC) experience poorer survival, partly due to differences in treatment and access to care. However, these factors do not fully explain survival disparities, and outcomes among other groups remain understudied. Emerging evidence also suggests racial differences in molecular subtypes. The Kaiser Permanente Northern California (KPNC) Research on Ovarian Cancer Survival (KPROCS) study was established to evaluate how multilevel factors contribute to differences in EOC treatment and survival. Methods:KPROCS includes women diagnosed at KPNC between 2000 and 2022 with invasive epithelial ovarian, fallopian tube, or peritoneal cancers at age ≥18 years. Diagnostic slides underwent centralized pathology review to classify histotypes according to the 2020 World Health Organization criteria. Addresses at diagnosis were linked to geospatial data to assess healthcare accessibility to chemotherapy infusion centers and neighborhood characteristics. In 540 women with high-grade serous EOC, gene expression molecular subtypes are being characterized. Results:The cohort includes 6,067 women with EOC, including 359 Black, 798 Hispanic, 906 non-Hispanic Asian American and Pacific Islander (AAPI), and 3,971 NHW women. Descriptive analyses demonstrate subpopulation differences that may influence survival. For example, Black women were least likely to receive surgery (75%), whereas AAPI women were the most likely (91%). Overall, 19% of the cohort received neoadjuvant chemotherapy, with the highest proportion among Black women (25%). Conclusions:This integrative approach will provide new insights into persistent differences in EOC treatment and survival across population subgroups. Impact:KPROCS is a unique resource for EOC disparities research.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Background:Compared with non-Hispanic White (NHW) women, Black women with epithelial ovarian cancer (EOC) experience poorer survival, partly due to differences in treatment and access to care. However, these factors do not fully explain survival disparities, and outcomes among other groups remain understudied. Emerging evidence also suggests racial differences in molecular subtypes. The Kaiser Permanente Northern California (KPNC) Research on Ovarian Cancer Survival (KPROCS) study was established to evaluate how multilevel factors contribute to differences in EOC treatment and survival. Methods:KPROCS includes women diagnosed at KPNC between 2000 and 2022 with invasive epithelial ovarian, fallopian tube, or peritoneal cancers at age ≥18 years. Diagnostic slides underwent centralized pathology review to classify histotypes according to the 2020 World Health Organization criteria. Addresses at diagnosis were linked to geospatial data to assess healthcare accessibility to chemotherapy infusion centers and neighborhood characteristics. In 540 women with high-grade serous EOC, gene expression molecular subtypes are being characterized. Results:The cohort includes 6,067 women with EOC, including 359 Black, 798 Hispanic, 906 non-Hispanic Asian American and Pacific Islander (AAPI), and 3,971 NHW women. Descriptive analyses demonstrate subpopulation differences that may influence survival. For example, Black women were least likely to receive surgery (75%), whereas AAPI women were the most likely (91%). Overall, 19% of the cohort received neoadjuvant chemotherapy, with the highest proportion among Black women (25%). Conclusions:This integrative approach will provide new insights into persistent differences in EOC treatment and survival across population subgroups. Impact:KPROCS is a unique resource for EOC disparities research.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Summary and description of social environment data and measures, 2000, 2010, and 2020 Census Tracts.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Summary and description of social environment data and measures, 2000, 2010, and 2020 Census Tracts.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Distribution of selected characteristics among epithelial ovarian cancer (EOC) cases from the California Cancer Registrya, in the KPNC catchment region, by KPNC membership, 2000 to 2021.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Distribution of selected characteristics among epithelial ovarian cancer (EOC) cases from the California Cancer Registrya, in the KPNC catchment region, by KPNC membership, 2000 to 2021.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1. from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Supplementary Figure 1 shows a map of the KPROCS Cohort catchment area, which covers a broad portion of Northern and Central California. Within this area, participants were concentrated in the more populous counties, including Contra Costa, Alameda, Santa Clara, Sacramento, San Mateo, Marin, Sonoma, Napa, Solano, San Joaquin, Placer, and Fresno.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1. from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Supplementary Figure 1 shows a map of the KPROCS Cohort catchment area, which covers a broad portion of Northern and Central California. Within this area, participants were concentrated in the more populous counties, including Contra Costa, Alameda, Santa Clara, Sacramento, San Mateo, Marin, Sonoma, Napa, Solano, San Joaquin, Placer, and Fresno.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Classification of ICD-O-3 morphology codes into the 2020 World Health Organization epithelial ovarian cancer histotypes.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Classification of ICD-O-3 morphology codes into the 2020 World Health Organization epithelial ovarian cancer histotypes.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Selected patient and tumor characteristics by pathology review, Kaiser Permanente Research on Ovarian Cancer Survival (KPROCS) Cohort Study, 2000 to 2022.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Selected patient and tumor characteristics by pathology review, Kaiser Permanente Research on Ovarian Cancer Survival (KPROCS) Cohort Study, 2000 to 2022.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Selected patient and tumor characteristics of individuals with high-grade serous cancer (HGSC) by tissue acquisition for molecular analyses, Kaiser Permanente Research on Ovarian Cancer Survival (KPROCS) Cohort Study, 2000 to 2022.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Selected patient and tumor characteristics of individuals with high-grade serous cancer (HGSC) by tissue acquisition for molecular analyses, Kaiser Permanente Research on Ovarian Cancer Survival (KPROCS) Cohort Study, 2000 to 2022.
- 31 August 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (11) , 1817-1829
The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Background: Compared with non-Hispanic White (NHW) women, Black women with epithelial ovarian cancer (EOC) experience poorer survival, partly due to differences in treatment and access to care. However, these factors do not fully explain survival disparities, and outcomes among other groups remain understudied. Emerging evidence also suggests racial differences in molecular subtypes. The Kaiser Permanente Northern California (KPNC) Research on Ovarian Cancer Survival (KPROCS) study was established to evaluate how multilevel factors contribute to differences in EOC treatment and survival. Methods: KPROCS includes women diagnosed at KPNC between 2000 and 2022 with invasive epithelial ovarian, fallopian tube, or peritoneal cancers at age ≥18 years. Diagnostic slides underwent centralized pathology review to classify histotypes according to the 2020 World Health Organization criteria. Addresses at diagnosis were linked to geospatial data to assess healthcare accessibility to chemotherapy infusion centers and neighborhood characteristics. In 540 women with high-grade serous EOC, gene expression molecular subtypes are being characterized. Results: The cohort includes 6,067 women with EOC, including 359 Black, 798 Hispanic, 906 non-Hispanic Asian American and Pacific Islander (AAPI), and 3,971 NHW women. Descriptive analyses demonstrate subpopulation differences that may influence survival. For example, Black women were least likely to receive surgery (75%), whereas AAPI women were the most likely (91%). Overall, 19% of the cohort received neoadjuvant chemotherapy, with the highest proportion among Black women (25%). Conclusions: This integrative approach will provide new insights into persistent differences in EOC treatment and survival across population subgroups. Impact: KPROCS is a unique resource for EOC disparities research.
- 31 August 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (11) , 1817-1829
The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival
Background: Compared with non-Hispanic White (NHW) women, Black women with epithelial ovarian cancer (EOC) experience poorer survival, partly due to differences in treatment and access to care. However, these factors do not fully explain survival disparities, and outcomes among other groups remain understudied. Emerging evidence also suggests racial differences in molecular subtypes. The Kaiser Permanente Northern California (KPNC) Research on Ovarian Cancer Survival (KPROCS) study was established to evaluate how multilevel factors contribute to differences in EOC treatment and survival. Methods: KPROCS includes women diagnosed at KPNC between 2000 and 2022 with invasive epithelial ovarian, fallopian tube, or peritoneal cancers at age ≥18 years. Diagnostic slides underwent centralized pathology review to classify histotypes according to the 2020 World Health Organization criteria. Addresses at diagnosis were linked to geospatial data to assess healthcare accessibility to chemotherapy infusion centers and neighborhood characteristics. In 540 women with high-grade serous EOC, gene expression molecular subtypes are being characterized. Results: The cohort includes 6,067 women with EOC, including 359 Black, 798 Hispanic, 906 non-Hispanic Asian American and Pacific Islander (AAPI), and 3,971 NHW women. Descriptive analyses demonstrate subpopulation differences that may influence survival. For example, Black women were least likely to receive surgery (75%), whereas AAPI women were the most likely (91%). Overall, 19% of the cohort received neoadjuvant chemotherapy, with the highest proportion among Black women (25%). Conclusions: This integrative approach will provide new insights into persistent differences in EOC treatment and survival across population subgroups. Impact: KPROCS is a unique resource for EOC disparities research.